COPENHAGEN, Denmark, Sept. 29, 2026 -- Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announced the successful close of...


Relentlessly innovative, NuVasive develops and markets minimally disruptive surgical products and procedures for the spine. From its inception, it has focused on creating products, such as its nerve avoidance monitoring system, that contribute to faster, less invasive surgical procedures, speedier recovery times for patients, and shorter hospital stays.
NuVasive went public in 2004.